We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
-27.23%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$206M
AUM Growth
-$24M
Cap. Flow
+$47M
Cap. Flow %
22.79%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$49.6M

Top Sells

Rank Stock Value
1
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$2.46M
2
CERO
CERo Therapeutics
CERO
+$142K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
1
Beam Therapeutics
BEAM
$2.64B
$88.7M 43%
4,540,132
– –
MAZE
2
Maze Therapeutics
MAZE
$1.55B
$45.4M 22%
+4,120,053
New +$49.6M
RAPP
3
Rapport Therapeutics
RAPP
$1.98B
$37.5M 18.21%
3,728,738
– –
ERAS icon
4
Erasca
ERAS
$6.68B
$15.1M 7.34%
11,055,554
– –
VERV
5
DELISTED
Verve Therapeutics
VERV
$9.12M 4.42%
2,008,809
– –
GOSS icon
6
Gossamer Bio
GOSS
$68.9M
$8.78M 4.26%
8,055,916
– –
UBX
7
DELISTED
Unity Biotechnology
UBX
$1.05M 0.51%
1,004,817
– –
QTTB icon
8
Q32 Bio
QTTB
$456M
$532K 0.26%
320,482
– –
CERO
9
DELISTED
CERo Therapeutics
CERO
$16.1K 0.01%
1,105
-3,592
-76% -$142K
OMIC
10
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
– –
-126,630
Closed -$2.46M

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q1 2025 Portfolio in Review

As of Q1 2025, Arch Venture Management held 10 positions worth $206M, down 10% from $230M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management deployed $47M of net new capital in Q1 2025, opening 1 new position. Its largest new stake was Maze Therapeutics: 4,120,053 shares worth $45.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was CERo Therapeutics, an estimated $142K trimmed.

  • Arch Venture Management's largest Q1 2025 buy was Maze Therapeutics: 4,120,053 shares worth $45.4M.
  • Arch Venture Management's biggest Q1 2025 reduction was CERo Therapeutics, cutting an estimated $142K.
  • Arch Venture Management fully exited Singular Genomics Systems, Inc. Common Stock in Q1 2025, selling an estimated $2.46M.
  • Arch Venture Management's ten largest holdings make up 100% of its $206M portfolio in Q1 2025.
  • Arch Venture Management opened 1 new position and closed 1 in Q1 2025.
  • Arch Venture Management's portfolio value fell 10% quarter-over-quarter to $206M.

Based on Arch Venture Management's 13F filing for Q1 2025, filed 15 May 2025.